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Implications for policy makers
• Similar to other low- and middle-income countries (LMICs), Thailand is facing financial and non-financial challenges when introducing new, 
high cost vaccines into their national vaccination program and this creates a greater need for robust and evidence-based mechanisms when 
setting vaccine priorities.
• Since introducing universal health coverage (UHC) in 2002, the Thai government has integrated its vaccination program to be part of UHC 
scheme.  This led to the creation of a new mechanism for vaccine selection and prioritisation which can bring about misalignment between the 
2 national decision-making bodies responsible for vaccine introduction. 
• The newly proposed Total System Effectiveness (TSE) uses a multi-criteria decision analysis (MCDA) approach that may be useful for promoting 
evidence-based and demand driven vaccine selection and also help streamline different decision-making processes.
Implications for the public
Total System Effectiveness (TSE) was piloted in Thailand, which has established governance structures and accountable decision-making processes 
for immunization policy, to explore the potential use of TSE in assisting national policy-makers with prioritizing vaccines. The findings highlighted 
that TSE can be incorporated with existing country policy processes, and help in promoting evidence-based and demand driven vaccine selection. 
In addition, TSE may be able to help reconcile concerns from different decision-making bodies in a country, as is the case in Thailand, where 2 
committees are responsible for vaccine policy. Lessons learned from Thailand may be beneficial to other low- and middle-income countries (LMICs) 
looking to use the TSE approach to develop a systematic and transparent decision-making process for immunisation policy.  
Key Messages 
Abstract
Background: The World Health Organization (WHO) has developed the Total System Effectiveness (TSE) framework to 
assist national policy-makers in prioritizing vaccines. The pilot was launched in Thailand to explore the potential use of 
TSE in a country with established governance structures and accountable decision-making processes for immunization 
policy. While the existing literature informs vaccine adoption decisions in GAVI-eligible countries, this study attempts 
to address a gap in the literature by examining the policy process of a non-GAVI eligible country.
Methods: A rotavirus vaccine (RVV) test case was used to compare the decision criteria made by the existing processes 
(Expanded Program on Immunization [EPI], and National List of Essential Medicines [NLEM]) for vaccine prioritization 
and the TSE-pilot model, using Thailand specific data. 
Results: The existing decision-making processes in Thailand and TSE were found to offer similar recommendations on 
the selection of a RVV product. 
Conclusion: The authors believe that TSE can provide a well-reasoned and step by step approach for countries, especially 
low- and middle-income countries (LMICs), to develop a systematic and transparent decision-making process for 
immunization policy. 
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Background
Traditionally, ministries or departments of health had sole 
responsibility for health service policy at the national level. 
These entities oversaw agenda setting, policy formulation 
and policy implementation. However, this trend has changed 
rapidly in recent years with the rise of universal health coverage 
(UHC); many countries have established new powerhouses 
for their UHC management. For example, Social Insurance 
Administration Organization in Indonesia, National Health 
Agency in India, PhilHealth in the Philippines, and Vietnam 
Social Security Office in Vietnam. 
These institutional changes introduce new challenges for 
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vaccine policy, since the responsibility for vaccine priority 
setting is often shared by multiple bodies which may have 
different interests. These challenges are in addition to other 
contextual and process factors that limit national priority 
setting for vaccines in low- and middle-income countries 
(LMICs), including political power, financial constraints, the 
influence of donor and industry priorities, a lack of explicit 
frameworks and participation of key stakeholders, and the 
inappropriate use of priority setting criteria.1-5 One way of 
addressing some of the above mentioned challenges is to 
develop a framework for supporting successful priority setting. 
To this end we piloted a new priority setting framework for 
vaccines, Total System Effectiveness (TSE), which has been 
renamed to Capacity-led Assessment for Priority-setting of 
Immunization, in Thailand, where the vertical vaccination 
program, previously part of the Ministry of Public Health 
(MOPH), has been reclassified to be part of the newly 
established and autonomous public health authority called 
the National Health Security Office (NHSO).
The Thai National Expanded Program on Immunization 
(EPI) was first introduced in 1977.6 Since then, priority 
vaccines have been provided free of charge to all the eligible 
population at public healthcare facilities in Thailand. The 
EPI currently covers 9 vaccine preventable diseases, namely 
tuberculosis, hepatitis B, diphtheria, tetanus, pertussis, 
poliomyelitis, measles, mumps, rubella, Japanese encephalitis, 
influenza, and cervical cancer.7
Previously, vaccine prioritization and selection were 
the joint responsibility of the MOPH and the Advisory 
Committee on Immunization Practices (ACIP). The ACIP is 
a subcommittee under the National Vaccine Committee and 
forms the National Immunization Technical Advisory Group 
for Thailand. It was established with a mandate to propose 
priority vaccines to the National Vaccine Committee and 
formulate recommendations for new vaccine introductions 
into EPI. The ACIP committee consists of experts in various 
disciplines including vaccinology, immunology, virology, 
infectious diseases, epidemiology, public health, and 
preventive medicine, and is chaired by the Director General of 
the Department of Disease Control (DDC) under the MOPH. 
Before 2002, the DDC acted as a vertical program manager in 
charge of the selection, procurement and management of the 
EPI program and vaccine management within MOPH.6
Since the establishment of the UHC scheme in 2002, which 
currently covers 75% of the Thai population, the NHSO 
has held the UHC budget independently from the MOPH.8 
It has been responsible for the financial management of 
all medicines used under the UHC scheme, in addition to 
all vaccines used for entire population in the country. This 
has incited a new mechanism for vaccine prioritization and 
selection and altered the roles of ACIP and DDC/MOPH. 
The NHSO reference the National List of Essential Medicines 
(NLEM) as its pharmaceutical benefit package. The NLEM 
subcommittee, under the National Drug Committee 
(developed in 1981), is currently the decision-making body 
for selecting medicines and vaccines for the NLEM. The 
ACIP has shifted into an advisory role upon the creation of 
the subcommittee.
Having 2 separate systems for vaccine product prioritization 
can trigger disagreements on policy decisions regarding 
vaccine adoption by the UHC manager or its reference, ie, 
the NLEM subcommittee in Thailand. For example, human 
papillomavirus vaccine (HPV) was proposed by the ACIP 
long before its implementation by the NHSO in 2017 and 
other new vaccines such as Rotavirus vaccine (RVV) and 
pneumococcal conjugated vaccine (PCV) recommended by 
ACIP, are yet to be implemented by the NHSO. More detailed 
information on the ACIP and HPV case study is available in 
the literature published elsewhere.7,9,10
Misalignment between the vaccine advisory group and the 
policy-making body responsible for UHC benefit package 
development may be inevitable if the 2 adopt different 
perspectives on vaccine prioritization. Often, the technical 
advisory group on vaccines focus on safety and efficacy/
effectiveness of vaccine introduction, given the group is mostly 
comprised of clinicians and are less fixated on the financial and 
other political pressures in issuing a new vaccination policy. 
In contrary, the UHC benefit package committee is by nature 
concerned with implementation and financial sustainability. 
Priority-setting processes have been introduced to guide the 
reimbursement decisions, and health technology assessment 
(HTA) has been proposed as a priority-setting tool.1,11,12 HTA 
is defined as “the systematic evaluation of the properties 
and effects of a health technology, addressing the direct and 
intended effects of this technology, as well as its indirect and 
unintended consequences, and aimed mainly at informing 
decision-making regarding health technologies.”13 HTA has 
proven to help decision-makers improve the efficiency of 
resource allocation in Thailand.1,11,12,14
In 2018, the Health Intervention and Technology Assessment 
Program (HITAP) and the World Health Organization 
(WHO) undertook a pilot project to understand whether TSE 
approach could support the harmonization of the vaccine 
policy process in Thailand. TSE is a concept which primarily 
aims to strengthen country frameworks for evaluating vaccine 
products, as well as communicating the priorities expressed 
by countries to inform regional and global discussions on 
vaccine preferences. The TSE framework articulates the steps 
for a structured, systematic and transparent product selection 
process, based on multi-criteria decision analysis (MCDA).15 
The TSE pilot project was conducted in Indonesia, Mali, 
Thailand, and Zambia as an exploratory study to assess the 
feasibility and usefulness of the TSE approach to inform 
vaccine policy. Thailand was chosen to represent the pilot 
country with well-established priority setting processes 
and to compare TSE with such existing mechanisms. Using 
the MCDA approach,16 in Thailand’s pilot, TSE model was 
designed as a practical tool run on Excel® worksheets for 
supporting the development of immunization policy. TSE 
allowed local inputs to populate the model and in line with 
MCDA methodology, it scored vaccine performance against 
multi decision criteria. 
The objectives of this paper are firstly to review the decision-
making criteria and respective processes of ACIP and the 
subcommittee of NLEM in vaccine prioritization. Second, to 
explore whether TSE is a useful approach that can reconcile 
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the 2 current mechanisms in Thailand, by comparing the 
TSE outcomes with those of ACIP and the subcommittee 
of NLEM. Lastly, to discuss whether the lessons from “one 
country, two systems experience” in Thailand can be useful 
for other countries where the national immunization program 
are or will become part of the UHC benefit package in the 
future. The authors will conclude by discussing the potential 
applications of their findings to other LMIC settings. 
Methods
The TSE approach was piloted in Thailand, starting from 
April to December 2018. For the first objective, authors 
conducted document reviews of the term of reference for the 
ACIP and NLEM subcommittee members as well as other 
publicly available government documents,17,18 interviews with 
Secretariat of the ACIP and NLEM (1 person of each Secretariat 
team), group discussions through key vaccine-related 
stakeholders meetings for which their minutes are available 
via this link http://www.globalhitap.net/resources/reports-
publications-2/,19,20 and had direct observation of the meeting 
between the ACIP and NLEM on the RVV to understand 
the processes of the ACIP and NLEM subcommittee with 
regard to vaccine policy decisions. The documents review, 
the interview with Secretariat of the ACIP and NLEM, and 
the discussion during the stakeholder meetings were mainly 
centred on the overall governance, decision-making processes 
and criteria used for the vaccine prioritization and selection. 
Open-ended questions were deployed to collect qualitative 
information and provoke discussions in the stakeholder 
meeting on the points mentioned above. The discussions 
were translated into the narrative and figures/tables presented 
in the results section.
In order to consider the utility of the TSE approach in 
Thailand, the authors focused on the process-based approach, 
and used a one-vaccine case study of various RVV products 
employing TSE and both the ACIP and NLEM subcommittee 
methodology. Five hypothetical RVV product profiles were 
developed for the exercise and an excel-based MCDA model 
was developed specifically for the TSE-based RVV selection 
in Thailand (TSE pilot), incorporating parts of existing 
models including UNIVAC,21 V-TIA,22 and C4P.23 This TSE 
model comprised of 3 main components: decision criteria, 
estimation of the vaccine performance based on decision 
criteria, and a scoring and ranking process. 
Criteria to be included in the TSE model was decided 
during the first stakeholder meeting convened in May 2018 
with representatives from the NLEM subcommittee and 
ACIP, relevant ministry departments including DDC, health 
insurance, academicians, and manufacturers.19 Stakeholders 
were asked to complete an open-ended questionnaire stating 
their most important criteria for selecting a vaccine product 
in the Thai context and then to subsequently rank the criteria. 
Due to time constraints, inputs from 15 respondents were 
collected and the top 5 criteria were used as the decision 
criteria for the RVV selection model as decided by the 
stakeholders involved in the TSE pilot study. 
Thailand-specific input parameters were computed 
to make the model relevant locally and to generate the 
performance scores for the different vaccine products. 
Parameters inputs included epidemiological data (eg, birth 
cohort, disease burden and numbers of outpatient and 
hospitalization), vaccine characteristics (eg, vaccine efficacy 
and vaccination schedule), cost data and other parameters 
such as coverage and socio-economic status (Supplementary 
file 1, Table S1). Parameters were generated from government 
reports, published literature, and expert opinions. Vaccine 
characteristics of the 5 hypothetical vaccine products were 
modified to reflect the Thai context (Supplementary file 
1, Table S2). The detailed methodology for estimating the 
vaccine performance based on decision criteria are shown 
in Supplementary file 2. 1 USD was considered equivalent to 
33.25 baht as per the exchange rates on July 2, 2018 (https://
www.bangkokbank.com/). The threshold for the incremental 
cost-effectiveness ratio as current used in Thailand was set at 
160 000 THB per disability-adjusted life year averted.24
Scoring was done by giving 100 points to the best performing 
vaccine and 0 points to the least performing vaccine products. 
Aggregated scores of the vaccine products were generated 
by linking the scores on different criteria with the criteria 
weights. Within MCDA methodology, weights represent the 
value stakeholders place on the different decision criteria. 
Given that the pilot study could only reach out to a limited 
number of stakeholders for criteria selection, equal weights 
were assigned to all the decision criteria.
In the second stakeholder meeting conducted in August 
2018 in Thailand, the TSE findings were presented against 
the decision-making criteria set by the ACIP and NLEM 
subcommittee, as well as the TSE stakeholders (as a result of 
the first meeting).20
Results 
Process of Vaccine Prioritization and Selection in Thailand
The national vaccine policy in Thailand before and after UHC 
introduction in 2002 is depicted in Figure 1. The ACIP’s role 
remains the same in providing a recommendation on vaccine 
and immunization policy formation; however, the request 
needs to be passed to the subcommittee of the NLEM for the 
inclusion of new vaccines in the reimbursement list. For the 
vaccines not included in the NLEM vaccines list, individuals 
must bear the cost of the vaccines themselves.
MCDA has been applied to the process of vaccine 
prioritization and selection by both the ACIP and the 
subcommittee of the NLEM. The common criteria considered 
by both the ACIP and subcommittee of the NLEM are: disease 
burden, disease prevalence, vaccine safety and efficacy, and 
estimated budget. In addition to these common criteria, the 
ACIP also considers local vaccine production capacity while 
the subcommittee of the NLEM considers cost-effectiveness 
and equity. For vaccines considered by the NLEM, the ACIP 
serves as a platform for information exchange, and submits 
evidence on disease prevalence, diseases burden, safety and 
efficacy of vaccine to the NLEM subcommittee as inputs for 
their consideration. The ACIP recommendations typically 
focus on a list of vaccine types, eg, HPV vaccine, PCV, ranked 
by their preference order. However, the ACIP do not specify 
the branding of vaccine products to be included.
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The subcommittee of the NLEM, with support from Health 
Economic Working Group, then produces local evidence on 
cost-effectiveness and budget impact analysis to feed into 
the decision-making,8 ensuring the efficient allocation of 
resources and financial sustainability for the UHC payer. Like 
other medicines, NLEM adopts a “choose one policy” which 
translates as only one specific type of vaccine product/ brand 
being listed together with their maximum procurement price 
to inform procurement agencies eg, NHSO or hospitals.
Similarity and Differences in Between TSE and Existing 
Processes Used by Both Committees – The ACIP and the 
Subcommittee of the NLEM 
Similar to the ACIP and the subcommittee of the NLEM, 
TSE uses an MCDA approach. However, while the ACIP and 
NLEM have fixed criteria to consider, the criteria for TSE 
can be flexible based on the decision question at hand. The 
output from the quantitative stage of TSE provides a ranking 
of available options, as is with the ACIP process.
The top 5 criteria identified for the TSE approach, as ranked 
by stakeholders through the questionnaires, were found to 
be as follows: safety, health impact, budget impact, delivery 
costs and cost effectiveness. Safety, health impact and budget 
impact were ranked by 85%-93% of stakeholders to be among 
the top 5 criteria (Table 1). Table 2 summarizes the criteria 
used by the 3 different decision-making bodies.
When assessing the different types of RVV against the 
base case parameters, no vaccine product performed the best 
against all 5 criteria. The RVV selection model (TSE-pilot) 
found that RVV-3 was identified as the top-ranking vaccine, 
followed by RVV-2 and RVV-4 (Figure 2). 
Table 3 shows the quantitative results for the top ranked 
vaccines using the RVV selection model (results are elaborated 
in Supplementary file 1, Table S3).
When comparing the results of running the RVV selection 
test case using the ACIP, NLEM, and TSE approach, all 3 
reached similar conclusions (Table 4).
To compare the TSE-pilot, with the existing criteria in 
Thailand, the scores and rankings of the 5 hypothetical RVVs 
were evaluated against the ACIP and the subcommittee of 
the NLEM criteria (Table 5). Thailand’s established priority 
setting mechanisms, the NLEM and ACIP, offered RVV-3 as 
the optimal choice. In the case of the NLEM process, where 
only one product can be selected in its “choose one policy,” 
Figure 1. The National Vaccine Policy in Thailand Before and After UHC Introduction in 2002. Abbreviation: UHC, universal health coverage.
Table 1. Top Decision Criteria Based on Rankings in a Local Stakeholder Meeting
Healthcare Priority Working Definition Used in RVV Selection Model (TSE-Pilot) Number of Votes 
Health impact/effectiveness/efficacy Rotavirus cases averted with vaccination 15
Safety Number of Intussusception hospitalizations due to vaccine 14
Budget impact Overall 5-year budget impact including the cost of program 13
Delivery costs Transport and storage costs for vaccines 7
Cost-effectiveness Incremental costs per DALY saved 3
Burden of disease Population size affected by the disease 3
Access to vaccine Availability of the vaccine 2
Vaccine security Ease of vaccine procurement and production security 2
Equity Coverage across different society strata by income quintiles 1
Abbreviations: DALY, disability-adjusted life year; TSE, Total System Effectiveness; RVV, rotavirus vaccine.
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RVV-3 would be added to the benefits package. For the ACIP, 
the results indicate that RVV-3 would be ranked first, RVV-
2 would be ranked second and RVV-1, 4, and 5 would be 
ranked third.
As detailed in Table 4, the ACIP criteria ranked the bottom 
3 vaccine products with an equivalent score at rank 3, whereas 
the RVV selection model (TSE-pilot) was able to discriminate 
between the 3 vaccine products with its scoring and ranking 
methodology. 
Discussion 
To our knowledge, this is the first study examining the 
application of the TSE concept for vaccine introduction 
in LMICs. The WHO is piloting TSE as an approach for 
promoting evidence-based, demand driven vaccine selection, 
in line with existing country policy processes. Given that TSE 
allows multiple decision-making criteria to be incorporated 
in a transparent and systematic manner, it may be able to 
help reconcile concerns currently faced by different decision-
making bodies in a country with 2 separate public health 
authorities responsible for policy development and holding 
technical advisory roles, as is the case with ACIP and NLEM 
subcommittee in Thailand.
We found that the 3 priority setting approaches, ie, the 
ACIP’s, NLEM’s and TSE offered the same policy choice. 
This may be explained by the fact that all the 3 approaches 
are based on MCDA with a similar qualitative aspect, use 
of quantitative evidence and had some overlapping criteria 
(ie, cost and outcomes/effectiveness data related to vaccine 
use). Although the top ranked vaccine product may not 
have performed best on all relevant criteria and is also not 
the cheapest vaccine option, it emerges as an optimal choice 
based on the MCDA used by all 3 approaches. 
A major difference between the 3 processes is the 
mechanism by which criteria is selected and included. In the 
TSE framework, criteria are chosen according to the decision 
question at hand, whereas in ACIP and subcommittee of 
NLEM deliberations, the criteria is already articulated.1,8 
Since there are well-established decision-making frameworks 
and governance in Thailand, such flexibility may not be 
necessary. However, when considering TSE at the global level, 
this flexibility to select the criteria based on decision question 
can allow for better discrimination between options. This 
would encourage countries to identify the decision criteria 
that is locally relevant, and may prompt the consideration 
of a broader set of criteria than the scientific considerations 
Figure 2. Ranking of the 5 Hypothetical RVVs From the RVV Selection Model (TSE-Pilot). Abbreviations: DALY, disability-adjusted life year; TSE, Total System 
Effectiveness; RVV, rotavirus vaccine.
Table 2. Criteria Considered in the 3 Decision-Making Approaches for Vaccine Product Prioritization
Criterion Considered by ACIP Considered by NLEM Identified by Stakeholders Through TSE Approach
Disease burden Yes Yes Yes (under ‘health impact’)
Disease prevalence Yes Yes Yes (under ‘health impact’)
Vaccine efficacy Yes Yes Yes (under ‘health impact’)
Vaccine safety Yes Yes Yes
Budget impact Yes Yes Yes
Cost-effectiveness No Yes Yes
Capacity for local manufacturing Yes No No
Equity No Yes No
Delivery cost No No Yes
Abbreviations: ACIP, Advisory Committee on Immunization Practices; NLEM, National List of Essential Medicine; TSE, Total System Effectiveness.
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commonly considered by National Immunization Technical 
Advisory Groups. 
Differences in perspectives and definitions of the criteria 
adopted in the 3 approaches were observed. For example, 
the ACIP includes disease burden in the way of measuring 
health impact and measuring case fatality rate whereas the 
RVV selection model (TSE-pilot) captures rotavirus cases 
averted as an indicator to account for the health impact. In 
addition, the application of the ACIP and NLEM criteria 
to different products of the same vaccine may not be able 
to differentiate if based on the epidemiological criteria eg, 
disease prevalence and burden. TSE can be seen as having an 
advantage over the ACIP mechanism as it is able to make a 
stronger differentiation between products of the same vaccine 
type. TSE can be designed to include a wide range of criteria 
for a one-vaccine evaluation. Whereas the ACIP mechanism 
has been established with the purpose of evaluating across 
vaccine types, with a strong focus on clinical aspects. Thus, 
in this study, while TSE could identify differences in each 
products performance in preventing rotavirus cases, ACIP 
ranked all 5 products the same in terms of disease burden and 
prevalence. 
During the first stakeholder meeting, the chair of the 
Table 3. Results From RVV Selection Model (TSE-Pilot) for the Top 5 Criteria Ranked by Thai Stakeholders
Base-Case ‘No Vaccine’ Scenario
Size of birth cohort 679 502
Total number of cases from 0-59 months 337 596
Total hospitalizations 50 054
Total deaths 74
Total healthcare cost spent 6.77 million USD









Safety Number of intussusception cases 4 11 3 5 19
Health impact Number of cases averted 77 776 58 265 114 295 80 984 56 239
Delivery costs Delivery and storage costs (USD) 8102 47 142 123 584 534 635 332 529
Cost-effectiveness ICER in comparison to no vaccine (USD/DALY averted) 1254 1866 6830 7125 7113
Budget impact 5-year budget impact (million USD) 8.83 9.57 65.76 48.55 30.37
Abbreviations: RVV, rotavirus vaccine; TSE, Total System Effectiveness; DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio.
Table 4 Ranking of the 5 Hypothetical RVVs Comparing 3 Priority Setting Tools, 




RVV-1 Rank 3 - Rank 5
RVV-2 Rank 2 - Rank 2
RVV-3 Rank 1 Rank 1 Rank 1
RVV-4 Rank 3 - Rank 3
RVV-5 Rank 3 - Rank 4
Abbreviations: RVV, rotavirus vaccine; TSE, Total System Effectiveness; ACIP, 
Advisory Committee on Immunization Practices; NLEM, National List of 
Essential Medicines.
a NLEM applies ‘choose one policy,’ it does not generate ranks for all the 
vaccine products.
subcommittee of the NLEM expressed the importance 
of decision-making bodies on health intervention and 
technology adoption being independent and policy neutral.19 
They highlighted the value in the ACIP and the subcommittee 
of the NLEM fulfilling different functions as it enables the 2 
committees to hold each other account. In the current status 
quo, the ACIP make an initial shortlist based predominantly 
on public health benefit, then the subcommittee of NLEM 
considers whether there is an economic argument for adding 
the recommended vaccine to the benefits package, in view 
of health interventions more broadly. Thus creating a check-
balance mechanism that ensures that the introduction of a 
new and high-cost vaccine to the national reimbursement list 
is cost-effective, sustainable and affordable for the country. 
Nonetheless, the exercise of utilizing the TSE framework 
jointly with ACIP and NLEM could encourage a platform 
for deliberation in terms of the stakeholders, criteria, and 
the evidence involved in each process and could bring about 
better alignment between the 2. This may be true for other 
countries in which the immunization and broader UHC 
decision-making processes or financing streams are not 
combined. TSE may thus be able to help reconcile different 
interests and concerns regarding vaccine introduction policy 
between different priority setting agencies in UHC countries. 
This study highlighted that, if used in real policy, the 
TSE approach may bring about a significant shift in the 
political and economic aspects of vaccine decision-making 
in Thailand. Given that TSE requires technical expertise in 
economics and modelling, individual with these skills set eg, 
health economists, analysts, technocrats would need to play a 
more active role in advising policy than in the current system 
at the ACIP, which focuses predominantly on the clinical 
aspects of the vaccine. Although the NLEM applies health 
economic evidence alongside clinical information, there is 
a deliberative process that allows qualitative data (such as 
urgency and equity concerns) to be included in the decision-
making process. The quantitative TSE model was more rigid 
in this sense, though it can make vaccine decisions more 
transparent and consistent. 
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Table 5. Results of the 5 Hypothetical RVVs Used in the RVV Selection Model (TSE-Pilot) in Thailand, Against the ACIP and NLEM Criteria
Criteria Outputs From RVV Selection Model (TSE-Pilot)
Scoring
RVV-1 RVV-2 RVV-3 RVV-4 RVV-5
Criteria by ACIP
1. Disease prevalence (size of 
population affected) 337 596 5 5 5 5 5
2.Disease burden (case fatality rate) 0.02% 1 1 1 1 1
3.Vaccine effectiveness
Total case averted 
No vaccine = 337 596
RVV-1 = 56 239 (16.7%)
RVV-2 = 58 265 (17.3%)
RVV-3 = 77 776 (23.0%)
RVV-4 = 114 295 (33.9%)
RVV-5 = 80 984 (24.0%)
1 1 1 1 1
4.Vaccine safety 
Incidence of intussusception cases (1-7 
days risk period), per 100 000 per year
RVV-1 = 19 (0.02%)
RVV-2 = 11 (0.01%)
RVV-3 = 4 (0.004%)
RVV-4 = 3 (0.003%)
RVV-5 = 5 (0.005%)
4 4 5 5 5
5. Budget impact 
5-year budget impact (THB)
RVV-1 = 1033 million 
RVV-2 = 325 million 
RVV-3 = 105 million 
RVV-4 = 2236 million 
RVV-5 = 1651 million 
2 4 5 1 1
6. Vaccine production in country NA Hypothetical RVV
Total scores (out of 25) 13 15 17 13 13
NLEM’s Additional Criteria to ACIPa
1. Cost-effectiveness analysis
ICER, compared to ‘No vaccine’ 
scenario (THB per DALY loss averted)
RVV-1 = 242 000 THB
RVV-2 = 63 500 THB
RVV-3 = 12 000 THB
RVV-4 = 232 300 THB
RVV-5 = 242 200 THB





2. Budget impact 
5-year budget impact (THB)
RVV-1 = 1033 million 
RVV-2 = 325 million 
RVV-3 = 105 million 
RVV-4 = 2236 million 
RVV-5 = 1651 million 
1033 million 325 million 105 million 2236 million 1651 million
3. Equity across health problems NA Hypothetical RVV
Abbreviations: ACIP, Advisory Committee on Immunization Practices; ICER, incremental cost-effectiveness ratio; NA, not applicable; NLEM, National List of 
Essential Medicines; RVV, rotavirus vaccine; THB, Thai Baht; TSE, Total System Effectiveness; DALY, disability-adjusted life year.
a NLEM applies ‘choose one policy,’ it does not generate ranks for all the vaccine products.
There are some limitations in the study design. While the 
RVV selection model developed to reflect the TSE approach 
provided the flexibility to incorporate country priority issues 
and generate good quality quantitative evidence, it required 
locally relevant specific inputs (parameters). Precision 
decisions depends on an accuracy and quality of data which 
can be difficult for other LMIC settings faced with data 
challenges. Similarly, implementation of the model requires 
technical capacity to be able to perform the analysis. These 
challenges can be more evident once the 4 country pilots 
have been carried out. In addition, the model focused on 
quantifiable criteria that can be measured in a numerical 
format. As a result, some policy concerns regarding the 
introduction of new vaccines such as equitable access or 
domestic vaccine production capacity, cannot be easily 
incorporated in a quantitative model as shown in the case 
study. Lastly, inputs from a limited number of respondents 
were included and only the top 5 decision-making criteria 
was collected, for example representatives from the public 
and/or civil society were absent from the first meeting. 
However, this is an exploratory study and to this end the 
study was not designed to reach all relevant stakeholders in 
the Thai healthcare system for eliciting the decision criteria. 
The analysis applied equal weights across the TSE criteria 
for simplicity due to the non-representativeness of the 
stakeholder participation in the meeting. The readers should 
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keep in mind the potential impact of the above limitations on 
the study findings.
Conclusion 
Findings from the Thailand pilot indicate that TSE may be a 
beneficial approach for LMICs that have not yet developed 
strong and accountable decision-making processes and 
governance structures for immunization policy. TSE has the 
potential to provide a well-reasoned and systematic approach 
for these countries, as a starting block for structured and 
transparent decision-making for vaccine product selection. 
Furthermore, TSE could be of value to a broader set of 
countries, including Thailand, for aligning prioritization 
mechanisms and thus as a foundation to help streamline 
vaccine policy processes. 
Acknowledgements
This study was funded by Bill and Melinda Gates Foundation. 
HITAP is funded by the Thailand Research Fund under the 
senior research scholar on Health Technology Assessment 
[grant numbers RTA5980011] and MOPH, Thailand. HITAP 
is part of the International Decision Support Initiative (https://
www.idsihealth.org/), which supports countries to get the 
best value for money from health spending. International 
Decision Support Initiative receives funding support from 
the Bill & Melinda Gates Foundation, the UK Department for 
International Development, and the Rockefeller Foundation. 
The findings, interpretations and conclusions expressed 
in this article do not necessarily reflect the views of the 
aforementioned funding agencies. The authors would like 
to thank Ms. Manushi Sharma and Mr. Md Rajibul Islam 
for their contribution to this project as co-investigators. The 
views expressed are theirs and do not necessarily represent 
the views of the WHO.
Ethical issues 
The method of this study was to analyse the secondary data, and did not involve 
the use of patient data. Therefore, ethical approval is not required.
Competing interests 
SB is a WHO consultant and RH is a WHO staff member. 
Authors’ contributions 
All authors attest they meet the ICMJE criteria for authorship. WR, YT, JL, 
SB, BG, and RCWH contributed to conception and design of the study. WR, 
YT, and RAA conducted the review and analysis of comparing TSE approach 
with Thailand’s processes. RK and JL conducted the TSE model (pilot study in 
Thailand). WR, RK, and YT interpreted the results. WR, RK, and YT drafted the 
manuscript. All authors revised the manuscript and approved the final version. 
YT, BG, and RCWH provided supervision to the overall of the TSE pilot study 
in Thailand.
Authors’ affiliations
1Health Intervention and Technology Assessment Program (HITAP), Ministry of 
Public Health, Nonthaburi, Thailand. 2Saw Swee Hock School of Public Health, 
National University of Singapore, Singapore, Singapore. 3Asc Academics, 
Groningen, The Netherlands. 4World Health Organization (WHO), Genève, 
Switzerland.
Supplementary files
Supplementary file 1 contains Tables S1-S3 and Supplementary file 2 shows 
the detailed methodology for estimating the vaccine performance based on 
decision criteria.
References
1. Pooripussarakul S, Riewpaiboon A, Bishai D, Muangchana C, 
Tantivess S. What criteria do decision makers in Thailand use to set 
priorities for vaccine introduction? BMC Public Health. 2016;16:684. 
doi:10.1186/s12889-016-3382-5
2. Burchett HE, Mounier-Jack S, Griffiths UK, et al. New vaccine 
adoption: qualitative study of national decision-making processes 
in seven low- and middle-income countries. Health Policy Plan. 
2012;27 Suppl 2:ii5-16. doi:10.1093/heapol/czs035 
3. Howard N, Bell S, Walls H, et al. The need for sustainability and 
alignment of future support for National Immunization Technical 
Advisory Groups (NITAGs) in low and middle-income countries. 
Hum Vaccin Immunother. 2018;14(6):1539-1541. doi:10.1080/216
45515.2018.1444321 
4. Mantel C, Wang SA. The privilege and responsibility of having 
choices: decision-making for new vaccines in developing countries. 
Health Policy Plan. 2012;27 Suppl 2:ii1-4. doi:10.1093/heapol/
czs041
5. Wallace L, Kapirir L. How are new vaccines prioritized in low-
income countries? a case study of human papilloma virus vaccine 
and pneumococcal conjugate vaccine in Uganda. Int J Health Policy 
Manag. 2017;6(12):707-720. doi:10.15171/ijhpm.2017.37 
6. Muangchana C, Thamapornpilas P, Karnkawinpong O. Immunization 
policy development in Thailand: the role of the Advisory Committee 
on Immunization Practice. Vaccine. 2010;28 Suppl 1:A104-109. 
doi:10.1016/j.vaccine.2010.02.043 
7. Expanded Programme on Immunization. Division of Vaccine 
Preventable Diseases, Ministry of Public Health website. http://
dvpd.ddc.moph.go.th/.  Accessed December 27, 2018.
8. Patcharanarumol W, Panichkriangkrai W, Sommanuttaweechai 
A, Hanson K, Wanwong Y, Tangcharoensathien V. Strategic 
purchasing and health system efficiency: a comparison of two 
financing schemes in Thailand. PLoS One. 2018;13(4):e0195179. 
doi:10.1371/journal.pone.0195179 
9. Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic 
evaluation of policy options for prevention and control of cervical 
cancer in Thailand. Pharmacoeconomics. 2011;29(9):781-806. 
doi:10.2165/11586560-000000000-00000 
10. Tantivess S, Yothasamut J, Putchong C, Sirisamutr T, 
Teerawattananon Y. The role of health technology assessment 
evidence in decision making: the case of human papillomavirus 
vaccination policy in Thailand. Nonthaburi: The Graphico Systems 
Co., Ltd; 2009. 
11. Mohara A, Youngkong S, Velasco RP, et al. Using health technology 
assessment for informing coverage decisions in Thailand. J Comp 
Eff Res. 2012;1(2):137-146. doi:10.2217/cer.12.10 
12. Leelahavarong P, Doungthipsirikul S, Kumluang S, et al. Health 
Technology Assessment in Thailand: Institutionalization and 
Contribution to Healthcare Decision Making: Review of Literature. 
Int J Technol Assess Health Care. 2019:1-7. doi:10.1017/
s0266462319000321 
13. HTA glossary. International Network of Agencies for Health 
Technology Assessment (INAHTA) website.  http://www.inahta.org/. 
Accessed August 8, 2019.
14. Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. 
The use of economic evaluation for guiding the pharmaceutical 
reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 
2014;108(7):397-404. doi:10.1016/j.zefq.2014.06.017 
15. Botwright S, Hutubessy R, Kahn A, Giersing B. A novel approach 
to evaluate the value of vaccines from the perspective of low and 
middle income countries: a conceptual framework and pilot project 
experience. Unpublished manuscript. World Health Organization; 
2019.
16. Baltussen R, Niessen L. Priority setting of health interventions: 
the need for multi-criteria decision analysis. Cost Eff Resour Alloc. 
2006;4:14. doi:10.1186/1478-7547-4-14 
17. National Vaccine Institute Web site. http://www.nvi.go.th/.  Accessed 
July 4, 2018.
18. National Drug Information. Thai Food and Drug Administration, 
Ministry of Public Health website. http://ndi.fda.moph.go.th/. 
Accessed July 4, 2018.
19. Health Intervention and Technology Assessment Program. Minutes 
Rattanavipapong et al
International Journal of Health Policy and Management, 2020, 9(10), 439–447 447
of stakeholder meeting on 17 May 2018: Introduction to Total 
Systems Effectiveness (TSE) pilot project in Thailand. Nonthaburi: 
Health Intervention and Technology Assessment Program; 2018.
20. Health Intervention and Technology Assessment Program. 
Stakeholder Dissemination Meeting: Total Systems Effectiveness 
(TSE) Pilot Project in Thailand. Nonthaburi: Health Intervention and 
Technology Assessment Program; 2018.
21. Jauregui B, Janusz CB, Clark AD, et al. ProVac Global Initiative: 
a vision shaped by ten years of supporting evidence-based policy 
decisions. Vaccine. 2015;33 Suppl 1:A21-27. doi:10.1016/j.
vaccine.2014.12.080 
22. Zehrung D, Jarrahian C, Giersing B, Kristensen D. Exploring 
new packaging and delivery options for the immunization 
supply chain. Vaccine. 2017;35(17):2265-2271. doi:10.1016/j.
vaccine.2016.11.095 
23. World Health Organization (WHO). WHO Cervical Cancer 
Prevention and Control Costing (C4P) Tool. Geneva: WHO; 2012.
24. The Health Economic Working Group. Meeting of the Health 
Economic Working Group on 22 May 2013. Nonthaburi: Food and 
Drug Administration, Ministry of Public Health; 2013.
